Research
Hormonal
Tirzepatide effectively reduces glucose levels and body weight in patients with type 2 diabetes and/or obesity.
Clinicians can consider tirzepatide as a treatment option for managing glucose levels and weight in these patients.
StrongSupportsmedium confidence
Tirzepatide effectively reduces glucose levels and body weight in patients with type 2 diabetes and/or obesity.
Why this rating
Based on data from phase 3 clinical trials.
Source
The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes
Ioannis Avgerinos et al. · Expert Opinion on Drug Discovery · 2024
DOI 10.1080/17460441.2024.2324918
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →